Literature DB >> 9726671

Antiviral treatment of idiopathic sudden sensorineural hearing loss: a prospective, randomized, double-blind clinical trial.

R J Stokroos1, F W Albers, E M Tenvergert.   

Abstract

A subclinical viral labyrinthitis has been postulated in the literature to elicit Idiopathic Sudden Sensorineural Hearing Loss. An etiological role for the herpes virus family is assumed. Corticosteroids possess a limited beneficial effect on hearing recovery in ISSHL. In this study, the therapeutic value of the antiherpetic drug aciclovir (Zovirax) on hearing recovery in 44 ISSHL patients receiving prednisolone is evaluated in a multicentre clinical trial. The study is designed prospectively, randomized, double-blind and placebo-controlled. Subjective parameters include hearing recovery, a pressure sensation on the affected ear, disequilibrium or vertigo and tinnitus. Audiometric parameters include pure tone and speech audiometry. A one-year follow up is obtained. Both the pressure sensation and disequilibrium or vertigo have a good prognosis, but tinnitus, occurring in most patients, has a poor prognosis. Hearing recovery prognosis depends on the severity of initial hearing loss, and not on vestibular involvement. No beneficial effect from combining aciclovir with prednisolone can be established in ISSHL.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9726671     DOI: 10.1080/00016489850154603

Source DB:  PubMed          Journal:  Acta Otolaryngol        ISSN: 0001-6489            Impact factor:   1.494


  17 in total

1.  Therapy of hearing disorders - conservative procedures.

Authors:  Stefan Plontke
Journal:  GMS Curr Top Otorhinolaryngol Head Neck Surg       Date:  2005-09-28

Review 2.  The inner ear and the neurologist.

Authors:  Charlotte Agrup; Michael Gleeson; Peter Rudge
Journal:  J Neurol Neurosurg Psychiatry       Date:  2007-02       Impact factor: 10.154

Review 3.  Sudden deafness: is it viral?

Authors:  Saumil N Merchant; Marlene L Durand; Joe C Adams
Journal:  ORL J Otorhinolaryngol Relat Spec       Date:  2008-02-01       Impact factor: 1.538

4.  How long should the sudden hearing loss patients be followed after early steroid combination therapy?

Authors:  In Seok Moon; Jin Kim; So-Yoon Lee; Hyun Seung Choi; Won-Sang Lee
Journal:  Eur Arch Otorhinolaryngol       Date:  2009-03-13       Impact factor: 2.503

5.  Sudden hearing loss: an effectivity comparison of intratympanic and systemic steroid treatments.

Authors:  Gülce Ermutlu; Nilda Süslü; Taner Yılmaz; Sarp Saraç
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-07-29       Impact factor: 2.503

6.  Regeneration of Cochlear Hair Cells and Hearing Recovery through Hes1 Modulation with siRNA Nanoparticles in Adult Guinea Pigs.

Authors:  Xiaoping Du; Qunfeng Cai; Matthew B West; Ibrahima Youm; Xiangping Huang; Wei Li; Weihua Cheng; Don Nakmali; Donald L Ewert; Richard D Kopke
Journal:  Mol Ther       Date:  2018-03-10       Impact factor: 11.454

7.  Corticosteroid treatment of idiopathic sudden sensorineural hearing loss: analysis of an RCT and material drawn from the Swedish national database.

Authors:  Elisabeth Hultcrantz; Ramesh Nosrati-Zarenoe
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-10-29       Impact factor: 2.503

Review 8.  Drug delivery for treatment of inner ear disease: current state of knowledge.

Authors:  Andrew A McCall; Erin E Leary Swan; Jeffrey T Borenstein; William F Sewell; Sharon G Kujawa; Michael J McKenna
Journal:  Ear Hear       Date:  2010-04       Impact factor: 3.570

9.  Prognostic effect of hyperbaric oxygen therapy starting time for sudden sensorineural hearing loss.

Authors:  Erol Yıldırım; K Murat Özcan; Mehmet Palalı; Mehmet Ali Cetin; Serdar Ensari; Hüseyin Dere
Journal:  Eur Arch Otorhinolaryngol       Date:  2013-11-24       Impact factor: 2.503

10.  Therapeutic effects of carbogen inhalation and lipo-prostaglandin E1 in sudden hearing loss.

Authors:  Hyun-Jin Lee; Chong Yoon Park; Jae Heon Lee; Hoon-Shik Yang; Joo Hyun Kim; Myung Jin Ban; In Seok Moon
Journal:  Yonsei Med J       Date:  2012-09       Impact factor: 2.759

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.